[en] Better supportive cares associated with better identification of sub-type of acute myeloid leukemia lead to a increase in survival amongst patients with AML. Introduction of the bitherapy of azacitine and venetoclax improve the care for older or unfit AML patient. Better strategies for hematopoietic stem cell transplantation decrease the morbidity and mortality associated with this procedure leading to an increase in OS.
Disciplines :
Hematology
Author, co-author :
De Voeght, Adrien ; Université de Liège - ULiège > Département des sciences cliniques
Language :
French
Title :
AML: new therapies - current and future
Publication date :
02 February 2024
Event name :
39th General Annual Meeting of the Belgian Hematology Society 2024
